The ability to produce antibody molecules by genetic engineering and gene transfection has revolutionized the study of structure/function relationships within the antibody molecule. Since human constant regions can be used chimeric antibodies provide for the first time a continuous source of antigen specific antibodies of all human isotypes. Increased understanding of the functional properties of antibodies should give insights into the basis for antibody caused diseases and should enable us to produce antibodies with the optimal combination of effector functions for immunotherapy. Our studies to date have focused on human IgG constant regions and have investigated the functional role of the hinge region and the constant region carbohydrate and more completely defined the residues recognized by FcgammaRI. We propose to expand our studies of IgG and will focus our attention on several questions. We will attempt to identify the residues which determine the differential ability of the IgG isotypes to activate complement. We will determine why IgG4 cannot activate C', why IgG2 is less effective than IgG1 and IgG3, and why IgG3 is better at binding C1q while IgG1 has been reported to be more efficient at C4 activation. With this information in hand we will attempt to produce an IgG more effective at C' activation both by in vitro mutagenesis and by making a polymeric IgG molecule. We will now shift our attention from FcgammaRI to FcgammaRII and FcgammaRIII and we determine their isotype specific binding patterns and the residues on IgG they recognize. Experiments have begun to characterize the specific residues recognized by rheumatoid factors (RFs) and will continue focusing on defining the epitopes on IgG3 recognized by monoclonal RFs. We have shown that chimeric IgG1 and IgG3 exhibit different serum half-lives in mice and will now attempt to identify the amino acid sequence determining serum half-life with the objective of producing antibodies with the optimal serum half-life in humans. We will also determine if human IgG2 non-covalently polymerizes. We will extend our studies to additional human isotypes focusing on IgD and IgA. A vector directing the synthesis of secreted chimeric IgD has been prepared and we will begin an analysis of the functional relationship within that molecule focusing on the role of carbohydrate and on defining the sequence determining binding to cellular receptors. An expression vector for human IgA1 has also been constructed. It is not known if the isotype of the light chain plays a role in the functional properties of the antibody molecule. We will now produce a chimeric light chain with human lambda constant region and compare the functional properties of the resulting antibodies with those with kappa light chains.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA016858-18
Application #
3164532
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1977-09-01
Project End
1994-02-28
Budget Start
1991-03-14
Budget End
1992-02-29
Support Year
18
Fiscal Year
1991
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Arts and Sciences
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Choi, Sung Hee; Kim, Byung-Gyu; Robinson, Janet et al. (2014) Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis. J Clin Invest 124:2472-82
Montano, Ramon F; Penichet, Manuel L; Blackall, Douglas P et al. (2009) Recombinant polymeric IgG anti-Rh: a novel strategy for development of direct agglutinating reagents. J Immunol Methods 340:1-10
Gala, Francoise A; Morrison, Sherie L (2004) V region carbohydrate and antibody expression. J Immunol 172:5489-94
Gala, Francoise A; Morrison, Sherie L (2002) The role of constant region carbohydrate in the assembly and secretion of human IgD and IgA1. J Biol Chem 277:29005-11
Helguera, G; Morrison, S L; Penichet, M L (2002) Antibody-cytokine fusion proteins: harnessing the combined power of cytokines and antibodies for cancer therapy. Clin Immunol 105:233-46
Montano, Ramon F; Morrison, Sherie L (2002) Influence of the isotype of the light chain on the properties of IgG. J Immunol 168:224-31
Penichet, M L; Morrison, S L (2001) Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 248:91-101
Trinh, K R; Morrison, S L (2000) Site-specific and directional gene replacement mediated by Cre recombinase. J Immunol Methods 244:185-93
Chan, L A; Lyczak, J B; Zhang, K et al. (2000) The novel human IgE epsilon heavy chain, epsilon tailpiece, is present in plasma as part of a covalent complex. Mol Immunol 37:241-52
Mateo, C; Lombardero, J; Moreno, E et al. (2000) Removal of amphipathic epitopes from genetically engineered antibodies: production of modified immunoglobulins with reduced immunogenicity. Hybridoma 19:463-71

Showing the most recent 10 out of 100 publications